癌症免疫疗法市场按治疗类型、作用机制、治疗方向、给药途径、适应症和最终用户划分－2025-2032 年全球预测

预计到 2032 年，癌症免疫治疗市场规模将成长至 1,207.5 亿美元，复合年增长率为 5.71%。

癌症免疫疗法发展的基本概述，重点介绍临床进展、营运挑战以及相关人员的策略要务

在持续的临床进展和监管里程碑的推动下，癌症免疫疗法已从一个充满希望的科学概念转变为癌症治疗的核心支柱。在过去十年中，利用免疫系统的治疗方法重新定义了骨髓恶性肿瘤和越来越多的固体癌的治疗模式，并在许多患者亚群中产生了有意义且持久的疗效。这一演变是由多种技术进步的融合所推动的，包括细胞工程、精准生物标记检测以及不断扩展的单株抗体、疫苗和病毒载体库。

随着研究的不断成熟，学术界和产业界的临床相关人员面临新的营运和策略挑战。研发人员必须在组合方案的科学复杂性与生产个人化产品的物流需求之间取得平衡，而支付者和医疗系统也日益要求提供长期价值和可控治疗途径的证据。因此，规划该领域治疗方案和服务的组织必须将转化科学与供应链弹性、监管协调和患者可及性模式等实际考量相结合，以实现规模化的临床效益。

本执行摘要整合了当前的动态、监管和商业阻力，以及相关人员可以采取的可行步骤，以应对不断变化的竞争和临床格局。其目标是提供清晰的、以证据为导向的叙述，以支持决策制定，同时又不掩盖肿瘤生物学、治疗方法或医疗服务环境的多样性。

影响免疫肿瘤学的关键转型趋势，包括技术创新、个人化策略和整个价值链的营运现代化

在科学突破、监管调整和相关人员期望不断变化等因素的共同推动下，癌症免疫疗法领域正在发生重大变革。首先，细胞疗法，尤其是嵌合体抗原受体T细胞成熟疗法，正从最初在血液学适应症中的成功应用，拓展到合成构建体和同种异体疗法，旨在扩大其应用范围并缩短治疗持续时间。查核点抑制技术的同步进展与更精细的免疫调节方法相辅相成，包括双特异性分子和旨在改善特异性和毒性特征的新一代抗体形式。

其次，转化科学正在加速个人化治疗方案的发展，例如新抗原疫苗、肿瘤浸润淋巴细胞优化以及基于生物标记的多重检测。因此，将临床专业知识与诊断和生物资讯能力相结合的合作研究至关重要。第三，製造和供应链创新，包括自动化、封闭式系统处理和区域化生产基地，正在改变开发商的规模化和商业化规划方式，虽然减少了一些障碍，但也带来了新的资本和监管复杂性。

第四，动态和付款方的动态正在影响治疗方法的评估方式，尤其强调长期疗效、基于价值的合约以及医疗体系的整合。单靠科学新颖性是不够的，还需要可靠的开发路径、强大的营运执行力以及以付款方为导向的证据产生。这些因素的结合将决定哪些项目能够从临床前景走向永续的临床和商业性影响。

评估 2025 年不断变化的关税政策将如何改变免疫疗法相关人员的供应链、製造策略和商业性定位

美国新关税政策的实施将持续到2025年，这可能对整个免疫肿瘤学生态系统产生累积影响，改变成本、供应链配置和采购决策。生物製药製剂和细胞疗法生产所需的专用试剂、一次性耗材、生物加工设备和低温运输物流服务通常在全球范围内采购。进口关税的提高和海关摩擦可能会增加到岸成本，促使企业进行库存审查，并加快寻找替代供应商的努力。这可能会导致采购前置作业时间延长，并给研发计画带来压力，因为应急计画已成为专案风险管理的关键组成部分。

为了应对关税带来的成本压力，许多相关人员可能会寻求近岸外包或国内製造伙伴关係，以减少跨境贸易波动带来的风险，并维持对关键生产过程的控制。虽然这种策略转变可能会增加前期投资负担，但也可能在供应连续性和法律规范方面带来长期效益。此外，不断上升的投入成本将促使人们更加严格地审查製造效率、製程集约化和产量比率优化，从而推动对自动化、封闭式系统和数位监控的投资，以在维持品质的同时保护净利率。

最后，关税变化的累积影响可能会影响商业策略，包括价格谈判、付款人合约以及产品发布时机。积极审查供应商关係、优先考虑弹性生产路径并向付款人透明地展示成本及其产生的价值的组织，将更有能力在受关税影响的市场环境中减轻财务和营运中断的影响。

综合細項分析突显了治疗方式、机制、适应症和护理环境的不同发展和商业化路径

细緻的细分框架揭示了临床差异化和商业性机会在治疗类型、机制、治疗线、给药途径、适应症和最终用户之间的交集。按治疗类型划分，项目包括癌症疫苗、CAR-T 疗法、CTLA-4 抑制剂、溶瘤病毒疗法、PD-1 抑制剂和 PD-L1 抑制剂，每种方案都考虑不同的开发挑战和临床定位。疫苗策略强调抗原选择和递送平台，而细胞疗法则需要製造创新和以患者为中心的物流。根据作用机制，该领域包括过继性细胞转移、查核点抑制剂、细胞激素疗法、溶瘤病毒疗法和疫苗疗法。这种机制多样性需要客製化生物标记策略、安全监测框架和组合假设，以在控制毒性的同时最大限度地提高疗效。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 整合单细胞定序数据以识别新型肿瘤抗原，用于个人化免疫治疗
• 针对固态肿瘤微环境的基因编辑增强CAR-T细胞治疗进展
• 新兴的微生物组调节策略可提高查核点抑制剂的反应率
• 引入人工智慧驱动的预测性生物标记物，用于早期评估患者对免疫疗法的反应
• 开发包含安全开关机制的现成同种异体 NK 细胞疗法
• 溶瘤病毒与免疫查核点抑制剂合併治疗难治性癌症

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 癌症免疫治疗市场（依治疗类型）

• 癌症疫苗
• CAR-T疗法
• CTLA-4抑制剂
• 溶瘤病毒疗法
• PD-1抑制剂
• PD-L1抑制剂

第九章 癌症免疫治疗市场（依作用机转）

• 过继细胞移植
• 查核点抑制剂
• 细胞激素治疗
• 溶瘤病毒疗法
• 疫苗治疗

第 10 章：癌症免疫疗法市场治疗线

• 第一行
• 从第四行开始
• 第二行
• 第三行

第11章 癌症免疫治疗市场（依给药途径）

• 肿瘤内
• 静脉
• 皮下

第十二章 癌症免疫治疗市场（按适应症）

• 造血系统恶性肿瘤
  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
• 固态肿瘤
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 黑色素瘤

第十三章 癌症免疫治疗市场（按最终用户）

• 医院
• 研究机构
• 专科诊所

第十四章 癌症免疫治疗市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 癌症免疫治疗市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 癌症免疫治疗市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • AstraZeneca PLC
  • Pfizer Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Sanofi SA
  • Gilead Sciences, Inc.

The Cancer Immunotherapy Market is projected to grow by USD 120.75 billion at a CAGR of 5.71% by 2032.

Foundational overview of cancer immunotherapy evolution highlighting clinical progress, operational challenges, and strategic imperatives for stakeholders

Cancer immunotherapy has moved from a promising scientific concept to a central pillar of oncology care, driven by a sustained wave of clinical advances and regulatory milestones. Over the past decade, therapies that harness the immune system have redefined treatment paradigms for both hematologic malignancies and a growing set of solid tumors, creating meaningful durable responses for many patient subgroups. This evolution has been propelled by a convergence of technological improvements in cell engineering, precision biomarker assays, and an expanding repertoire of monoclonal antibodies, vaccines, and viral vectors.

As research continues to mature, stakeholders across industry, academia, and clinical practice face a new set of operational and strategic questions. Developers must balance the scientific complexity of combination regimens with the logistical demands of manufacturing personalized products, while payers and health systems increasingly seek evidence of long-term value and manageable treatment pathways. Consequently, organizations planning therapeutics or services in this space must integrate translational science with pragmatic considerations such as supply chain resilience, regulatory alignment, and patient access models to realize clinical benefit at scale.

This executive summary synthesizes current dynamics, regulatory and commercial headwinds, and actionable avenues for stakeholders to navigate the changing competitive and clinical environment. The goal is to offer a clear, evidence-aligned narrative that supports decision-making without obscuring the heterogeneity of tumor biology, therapeutic modalities, or care delivery contexts.

Critical transformative trends reshaping immuno-oncology including technological innovation, personalized strategies, and operational modernization across the value chain

The landscape of cancer immunotherapy is undergoing transformative shifts driven by a combination of scientific breakthroughs, regulatory adaptations, and evolving stakeholder expectations. First, the maturation of cell therapies, particularly chimeric antigen receptor T cells, has expanded beyond early successes in hematologic indications toward engineered constructs and allogeneic approaches designed to broaden applicability and reduce time-to-treatment. Parallel advances in checkpoint inhibition have been complemented by more nuanced approaches to immune modulation, including bispecific molecules and next-generation antibody formats that seek improved specificity and toxicity profiles.

Second, translational science is accelerating personalized approaches-neoantigen vaccines, tumor-infiltrating lymphocyte optimization, and multiplexed biomarker-driven trials-that demand more intricate trial designs and real-world evidence capture. As a result, collaborations that pair clinical expertise with diagnostic and bioinformatics capabilities are becoming essential. Third, manufacturing and supply chain innovations, including automation, closed-system processing, and regionalized production hubs, are shifting how developers plan scale-up and commercialization, reducing some barriers but introducing new capital and regulatory complexities.

Fourth, market and payer dynamics are influencing how therapies are evaluated, with a pronounced emphasis on long-term outcomes, value-based contracting, and healthcare system integration. Collectively, these shifts are redefining competitive advantage: scientific novelty alone is insufficient without credible development pathways, robust operational execution, and payer-aligned evidence generation. The combination of these elements will determine which programs progress from clinical promise to sustainable clinical and commercial impact.

Assessment of how evolving tariff policies in 2025 could alter supply chains, manufacturing strategies, and commercial positioning across immunotherapy stakeholders

The introduction of new tariff policies in the United States during 2025 has the potential to exert a cumulative impact across the cancer immunotherapy ecosystem by altering costs, supply chain configurations, and sourcing decisions. Key inputs for biologic and cell therapy manufacturing-specialized reagents, single-use consumables, bioprocessing equipment, and cold-chain logistics services-are often sourced globally. An increase in import duties or customs friction can elevate landed costs, prompt inventory rebalancing, and accelerate efforts to qualify alternative suppliers. Consequently, research and development timelines may experience pressure as procurement lead times extend and contingency planning becomes a material component of program risk management.

In response to tariff-driven cost pressures, many stakeholders may pursue nearshoring or domestic manufacturing partnerships to reduce exposure to cross-border trade volatility and maintain control over critical production steps. Such strategic reorientation could increase upfront capital deployment but may also yield long-term advantages in supply continuity and regulatory oversight. Moreover, higher input costs will heighten scrutiny of manufacturing efficiency, process intensification, and yield optimization, incentivizing investments in automation, closed systems, and digital monitoring to protect margins while preserving quality.

Finally, the cumulative effects of tariff changes will likely influence commercial strategies including pricing negotiations, payer contracting, and the staging of product launches. Organizations that proactively reassess supplier relationships, prioritize resilient manufacturing pathways, and transparently demonstrate cost and outcome value to payers will be better positioned to mitigate financial and operational disruption in a tariff-influenced market environment.

Comprehensive segmentation analysis revealing where therapeutic modalities, mechanisms, indications, and care settings create distinct development and commercialization pathways

A nuanced segmentation framework illuminates where clinical differentiation and commercial opportunity intersect across therapy types, mechanisms, lines of therapy, administration routes, indications, and end users. Based on Therapy Type, programs span Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors, Oncolytic Virus Therapy, PD-1 Inhibitors, and PD-L1 Inhibitors, each presenting distinct development challenges and clinical positioning considerations; vaccine strategies emphasize antigen selection and delivery platforms, whereas cell therapies demand manufacturing innovation and patient-centric logistics. Based on Mechanism Of Action, the field encompasses Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy, and Vaccine Therapy, and this mechanistic diversity requires tailored biomarker strategies, safety monitoring frameworks, and combination hypotheses to maximize efficacy while managing toxicity.

Based on Line Of Therapy, therapeutic opportunities and payer expectations vary significantly between First Line, Second Line, Third Line, and Fourth Line And Beyond, with earlier-line approvals necessitating higher-evidence thresholds and clearer comparative benefit; consequently, developers should plan sequencing strategies that align trial design with expected reimbursement scenarios. Based on Route Of Administration, distinctions among Intratumoral, Intravenous, and Subcutaneous approaches influence clinical workflow, patient burden, and site-of-care economics, shaping adoption pathways across hospitals and clinics. Based on Indication, the landscape bifurcates into Hematologic Malignancies and Solid Tumors, with the former further segmented into Leukemia, Lymphoma, and Multiple Myeloma and the latter into Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma, each indication presenting unique tumor microenvironmental considerations and biomarker profiles that inform patient selection and combination strategies.

Based on End User, hospitals, research institutes, and specialty clinics play differentiated roles in clinical trial accrual, product administration, and post-market evidence generation; hospitals often lead high-complexity administrations and inpatient monitoring, research institutes drive translational science and early-phase innovation, while specialty clinics enable outpatient delivery models that can improve throughput and patient convenience. Together, this segmentation highlights where scientific focus, operational investment, and commercial engagement should be concentrated to address unmet needs and optimize development trajectories.

Region-specific dynamics and strategic considerations for regulatory engagement, evidence generation, and manufacturing across global immunotherapy markets

Regional dynamics shape clinical trial design, regulatory engagement, manufacturing investment, and access strategies, demanding region-specific approaches that accommodate regulatory frameworks, reimbursement systems, and healthcare infrastructure. In the Americas, regulatory agencies and payers emphasize robust outcomes evidence and real-world data, while large research networks and venture and corporate investment have accelerated first-in-human studies and commercialization pathways; consequently, organizations often prioritize North American clinical validation and payer dialogue early in development to underpin broader market access plans. The Americas also host concentrated manufacturing and logistics capabilities, which supports rapid scale-up but requires careful coordination with hospital and specialty clinic administration models.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement environments necessitate multi-jurisdictional regulatory strategies and differentiated pricing approaches. European health technology assessment bodies place particular weight on comparative effectiveness and cost-effectiveness assessments, influencing trial endpoints and evidence generation plans. Additionally, emerging markets across the Middle East & Africa present opportunities for capacity building and pilot access programs but require tailored operational partnerships and investment in cold-chain and training infrastructure.

In Asia-Pacific, accelerated trial recruitment, growing biotech innovation hubs, and increasing local manufacturing capacity are shaping regional strategies; countries in the region vary in regulatory timelines and local clinical expectations, prompting companies to calibrate development plans to leverage speed to data while ensuring quality and regulatory alignment. Cross-region collaboration, such as bridging studies and harmonized regulatory submissions, can reduce time-to-patient access and support global labeling strategies, provided sponsors anticipate regional clinical practice patterns and payer requirements.

Competitive dynamics and partnership-based strategies revealing how execution, manufacturing scale, and platform differentiation drive long-term value creation

The competitive landscape is characterized by incumbent immuno-oncology leaders and a large cohort of emerging biotechs pursuing platform innovation, niche indications, or combination regimens. Established developers have leveraged deep clinical datasets and manufacturing footprints to secure broad label expansions and to negotiate value-based arrangements with payers, whereas smaller firms often focus on differentiated biology, novel antigen targets, or enabling technologies that improve manufacturability and patient access.

Across the ecosystem, strategic partnerships between developers, contract development and manufacturing organizations, diagnostic providers, and academic centers have become increasingly common as a means to accelerate clinical translation and de-risk capital-intensive steps. These alliances frequently address discrete gaps such as vector manufacturing, T-cell engineering, or companion diagnostic validation, enabling faster trial starts and improved operational scalability. In parallel, service providers offering automation, analytics, and patient management tools are emerging as critical enablers for both personalized and standardized therapeutic approaches.

Intellectual property positioning, clinical differentiation, and demonstrated ability to execute complex supply chains remain decisive factors in value creation. Firms that combine robust clinical programs with scalable manufacturing, payer-aligned evidence strategies, and strong collaborative networks will retain strategic advantage. At the same time, new entrants that deliver platform-level improvements in safety, cost, or ease-of-use can rapidly gain relevance through licensing or co-development agreements.

Actionable strategic recommendations for aligning clinical development, manufacturing resilience, and payer engagement to accelerate adoption and value realization

Leaders planning to navigate the next phase of immuno-oncology advancement should adopt integrated strategies that align science, operations, and commercialization. First, prioritize modular development plans that allow for adaptive trial designs and biomarker-enriched cohorts to demonstrate meaningful benefit while preserving flexibility for label expansion and combinations. Early engagement with regulatory bodies and payers is essential to define clinically relevant endpoints and acceptable evidence packages that support durable reimbursement outcomes. Second, invest in manufacturing resilience by exploring regional production hubs, automation, and supplier diversification to mitigate geopolitical and tariff-related disruption while maintaining quality and compliance standards.

Third, cultivate strategic partnerships spanning diagnostics, contract manufacturing, and clinical network collaborators to accelerate translational pathways and reduce time-to-patient. By leveraging external expertise, organizations can focus internal resources on core differentiators such as target biology and clinical execution. Fourth, design patient-centric delivery models that reduce burden, enable outpatient administration where feasible, and integrate digital tools for monitoring and outcomes capture. These models enhance adherence and produce real-world evidence that reinforces payer negotiations and clinical adoption.

Finally, maintain disciplined portfolio management that balances novel, high-risk science with programs offering clearer paths to clinical and commercial viability. Establishing cross-functional governance for prioritization, risk monitoring, and go-to-market readiness will enable faster, more confident decisions as the scientific and policy environment evolves.

Robust multi-source research methodology integrating expert interviews, regulatory analysis, and operational assessments to generate actionable industry insights

The research synthesis draws on a multi-source methodology designed to integrate scientific literature, regulatory guidance, expert interviews, and operational insights to build a coherent narrative aligned with industry practice. Primary qualitative inputs included structured interviews with clinical investigators, manufacturing leads, payers, and commercial strategists to surface pragmatic barriers and enablers across development and delivery pathways. These interviews were complemented by a systematic review of peer-reviewed publications, regulatory approvals, and public filings to ensure the analysis reflects recent scientific advances and policy shifts.

Additionally, the methodology incorporated operational assessments of manufacturing and supply chain considerations through engagements with contract development and manufacturing organizations and logistics specialists. This allowed for an informed appraisal of practical constraints such as lead times, cold-chain requirements, and capacity scaling. Analytical synthesis emphasized cross-validation, pairing qualitative perspectives with documented clinical and regulatory milestones to reduce bias and enhance actionability. Throughout the research process, attention was paid to transparency of assumptions, the provenance of insights, and the identification of areas where further primary data collection could refine conclusions.

This multi-dimensional approach enables stakeholders to interpret findings in the context of their own strategic priorities while recognizing the heterogeneity inherent in therapeutic modalities, geographic markets, and care delivery models.

Concluding synthesis emphasizing the necessity of integrated scientific, operational, and commercial strategies to realize the full promise of immuno-oncology

Cancer immunotherapy stands at an inflection point where scientific progress must be matched by operational excellence and strategic clarity to sustain momentum. Novel modalities and combination strategies continue to expand the therapeutic toolkit, but their ultimate impact will depend on the ability of stakeholders to navigate complex manufacturing requirements, diverse regulatory expectations, and evolving payer evidence demands. Organizations that proactively adapt development strategies to incorporate biomarker-driven patient selection, resilient supply chains, and payer-aligned evidence will be better positioned to translate clinical promise into durable patient benefit.

Moreover, the growing interplay between regional regulatory environments and global commercialization strategies underscores the necessity of harmonized evidence plans and flexible manufacturing footprints. As new policy and trade dynamics emerge, including tariff considerations, the capacity to rapidly adjust sourcing and production approaches becomes a competitive advantage. In conclusion, the path forward requires integrated leadership across science, operations, and commercial functions to ensure that innovations in immuno-oncology are delivered efficiently, equitably, and with demonstrable value for patients and health systems alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of single-cell sequencing data to identify novel tumor antigens for personalized immunotherapy
• 5.2. Advancement in gene editing-enhanced CAR T-cell therapies targeting solid tumor microenvironment
• 5.3. Emergence of microbiome modulation strategies to improve checkpoint inhibitor response rates
• 5.4. Adoption of AI-driven predictive biomarkers for early assessment of patient response to immunotherapy
• 5.5. Development of off-the-shelf allogeneic NK cell therapies with engineered safety switch mechanisms
• 5.6. Combination approaches leveraging oncolytic viruses and immune checkpoint blockade for resistant cancers

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Market, by Therapy Type

• 8.1. Cancer Vaccines
• 8.2. CAR-T Therapy
• 8.3. CTLA-4 Inhibitors
• 8.4. Oncolytic Virus Therapy
• 8.5. PD-1 Inhibitors
• 8.6. PD-L1 Inhibitors

9. Cancer Immunotherapy Market, by Mechanism Of Action

• 9.1. Adoptive Cell Transfer
• 9.2. Checkpoint Inhibitors
• 9.3. Cytokine Therapy
• 9.4. Oncolytic Virus Therapy
• 9.5. Vaccine Therapy

10. Cancer Immunotherapy Market, by Line Of Therapy

• 10.1. First Line
• 10.2. Fourth Line And Beyond
• 10.3. Second Line
• 10.4. Third Line

11. Cancer Immunotherapy Market, by Route Of Administration

• 11.1. Intratumoral
• 11.2. Intravenous
• 11.3. Subcutaneous

12. Cancer Immunotherapy Market, by Indication

• 12.1. Hematologic Malignancies
  • 12.1.1. Leukemia
  • 12.1.2. Lymphoma
  • 12.1.3. Multiple Myeloma
• 12.2. Solid Tumors
  • 12.2.1. Breast Cancer
  • 12.2.2. Colorectal Cancer
  • 12.2.3. Lung Cancer
  • 12.2.4. Melanoma

13. Cancer Immunotherapy Market, by End User

• 13.1. Hospitals
• 13.2. Research Institutes
• 13.3. Specialty Clinics

14. Cancer Immunotherapy Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Cancer Immunotherapy Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Cancer Immunotherapy Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Merck & Co., Inc.
  • 17.3.2. Bristol-Myers Squibb Company
  • 17.3.3. F. Hoffmann-La Roche Ltd
  • 17.3.4. Novartis AG
  • 17.3.5. AstraZeneca PLC
  • 17.3.6. Pfizer Inc.
  • 17.3.7. Johnson & Johnson
  • 17.3.8. Amgen Inc.
  • 17.3.9. Sanofi S.A.
  • 17.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CANCER IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 247. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 250. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 296. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 297. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 298. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 299. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 300. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 301. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 302. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 303. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 304. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
• TABLE 307. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
• TABLE 308. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
• TABLE 309. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 310. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 311. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 312. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 313. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 314. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 315. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 316. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLIO